 |
 Video: What is a Stock Split?
|
|
|
| Sinovac Biotech is a holding company. Through its subsidiaries, Co. is a biopharmaceutical company that focuses on research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases. Co.'s products include: Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a vaccine against influenza; Panflu, a vaccine against the H5N1 influenza virus; Split Viron Pandemic Influenza Vaccine, an influenza vaccine; Panflu.1, a vaccine against the influenza A H1N1 virus; Mumps Vaccine; Inlive, a treatment for HFMD; and Varicella Vaccine, a vaccine for disease caused by the varicella-zoster virus. According to our Sinovac Biotech stock split history records, Sinovac Biotech has had 0 splits. | |
|
Sinovac Biotech (SVA) has 0 splits in our Sinovac Biotech stock split history database.
Looking at the Sinovac Biotech stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Sinovac Biotech shares, starting with a $10,000 purchase of SVA, presented on a split-history-adjusted basis factoring in the complete Sinovac Biotech stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
04/22/2014 |
|
| End date: |
02/22/2019 |
|
| Start price/share: |
$6.38 |
|
| End price/share: |
$6.47 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
1.41% |
|
| Average Annual Total Return: |
0.29% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$10,141.18 |
|
| Years: |
4.84 |
|
|
|
|
|
